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Cell Carcinoma Cells through an
Integrin α5– and Integrin
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Goethe-University, Frankfurt am Main, GermanyAbstract
Inhibitors of the mammalian target of rapamycin (mTOR) have improved the treatment of renal cell carcinoma
(RCC). However, chronic drug exposure may trigger resistance, limiting the utility of these agents. The metastatic
behavior of RCC cells, susceptible (RCCpar) or resistant (RCCres) to the mTOR inhibitor temsirolimus, was
investigated. Adhesion to vascular endothelium or immobilized collagen and fibronectin was quantified.
Chemotactic motility was evaluated with a modified Boyden chamber assay. Integrin α and β subtype receptors
were analyzed by flow cytometry and Western blot analysis. The physiological relevance of the integrins was then
determined by blocking studies and small interfering RNA knockdown. Adhesion to endothelial cells and to
fibronectin (not to collagen) and chemotaxis were enhanced in RCCres compared to RCCpar. RCCres detached from
fibronectin and motile activity further increased under retreatment with low-dosed temsirolimus. α5 integrin was
diminished inside the cell and at the cell surface, whereas the β3 subtype was reduced intracellularly but elevated
at the plasma membrane. In RCCpar, blocking α5 surface receptors enhanced RCC-collagen but reduced RCC-
fibronectin interaction, whereas the opposite was true for RCCres. Chemotaxis of RCCpar but not of RCCres was
strongly diminished by the α5 antibody. Blocking β3 significantly lowered chemotaxis with stronger effects on
RCCres, compared to RCCpar. Importantly, β3 knockdown reduced chemotaxis of RCCpar but upregulated the
motile behavior of RCCres. Temsirolimus resistance is characterized by quantitative alterations of integrin α5 and
β3 expression, coupled to functional changes of the integrin molecules, and forces a switch from RCC adhesion to
RCC migration.
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Renal cell carcinoma (RCC) is one of the most aggressive tumor
types. Approximately one third of patients have already developed
metastases at diagnosis, and up to 40% of patients undergoing
surgical resection will have disease recurrence. Once metastasized, the
5-year survival rate is less than 5% [1].
Increasing knowledge about the molecular alterations driving a cell to
become malignant has led to the development of novel compounds
targeting those pathways, which are aberrantly activated in cancer. This is
particularly true for the phosphatidyl inositol 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) signaling, which is dysregu-
lated in RCC [2], and activation of this pathway has been suggested to
correlate with aggressive behavior and poor prognosis in RCC tumors [3].In the targeted treatment of RCC, mTOR inhibition plays a
principal role. Temsirolimus has been approved for the first-line
treatment of patients with RCC with poor prognosis, whereas the oral
mTOR inhibitor everolimus has been recommended for patients withA
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endothelial growth factor–targeted therapy [1,4].
Though mTOR targeting offers significantly enhanced response
rates, it is rarely curative [5]. The reason for the insufficient
therapeutic response has not been fully elucidated. It is argued that
chronic drug exposure may activate an undesired escape mechanism,
leading to resistance development. It has recently been demonstrated
that long-term mTOR blockade triggers undesired feedback loops in
RCC cells [6], associated with drug nonresponsiveness and
accelerated tumor growth [7]. Similar effects have been observed
with resistant prostate cancer cells, evidenced by elevated cell cycle
progression compared to those from drug-sensitive sublines [8].
When discussing the pros and cons of mTOR inhibitors, it must be
kept in mind that invasion and metastasis are critical for malignant
tumor progression. They are the main causes of treatment failure.
How circulating RCC cells are transferred from blood vessels into the
target tissue when resistance toward mTOR inhibitors develops is
unclear. The object of the present study was to drive RCC cells into
temsirolimus resistance and investigate altered adhesion and invasion
dynamics. Because adhesion molecules of the integrin family are
critically involved in the process of tumor transmigration and
metastasis [9,10], modification of integrin α and β subtype expression
was analyzed and correlated to the invasive behavior of the tumor cells.Materials and Methods
Cell Culture
Kidney carcinoma Caki-1, KTCTL-26, and A498 cells were
purchased from LGC Promochem (Wesel, Germany). The tumor
cells were grown and subcultured in RPMI 1640 medium (Gibco/
Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf
serum (FCS), 100 IU/ml penicillin, and 100 μg/ml streptomycin at
37°C in a humidified 5% CO2 incubator. The temsirolimus-resistant
subline was cultivated for 12 months by exposing the parental cells
to temsirolimus (Torisel; LC Laboratories, Woburn, MA), starting at
1 nM/ml and increasing stepwise to 1 μM/ml. The resistant variants
were termed Cakires, KTCres, and A498res. The parental control cells
were designated Cakipar, KTCpar, and A498par.
Human umbilical vein endothelial cells (HUVEC) were isolated
from human umbilical veins and harvested by enzymatic treatment
with dispase (Gibco/Invitrogen). Human endothelial cells were
grown in Medium 199 (M199; Biozol, Munich, Germany),
supplemented with 10% FCS, 10% pooled human serum, 20 mg/
ml endothelial cell growth factor (Boehringer, Mannheim, Germany),
0.1% heparin, 100 ng/ml gentamycin, and 20 mMHepes buffer (pH
7.4). Subcultures from passages 2 to 5 were employed.
Drug Treatment
Temsirolimus was dissolved in DMSO as a 10 mM stock solution
and stored as aliquots at −20°C. Before experiments, temsirolimus
was diluted in cell culture medium to the final concentration. Control
cell cultures received cell culture medium alone. To exclude toxic
effects of the compounds, cell viability was determined by trypan blue
(Gibco/Invitrogen).
To analyze the influence of temsirolimus on adhesion and
chemotactic movement of resistant compared to sensitive tumor
cells, cell culture medium of Cakires, KTCres, or A498res cells
containing 1 μM temsirolimus was replaced by temsirolimus-free
medium to avoid unspecific effects. A medium change was also carriedout in the drug-sensitive cell culture system. After 3 days, 10 nM/ml
temsirolimus was added to both resistant and sensitive cells (controls
received fresh medium without temsirolimus), and adhesion and
chemotactic movement were analyzed.
Tumor Cell Adhesion
To analyze tumor cell adhesion,HUVECswere transferred to six-well
multiplates (Falcon Primaria; BD Biosciences, Heidelberg, Germany)
in complete HUVEC medium. When confluency was reached, RCC
cells (resistant and sensitive) were detached from their culture flasks
by Accutase treatment (PAA Laboratories, Cölbe, Germany). Cells
(0.5 × 106) were then added to the HUVEC monolayer for 30, 60, or
120 minutes. Subsequently, nonadherent tumor cells were washed
off using warmed (37°C) M199. The remaining cells were fixed with
1% glutaraldehyde. Adherent tumor cells were counted in five different
fields of a defined size (5 × 0.25mm2) using a phase-contrastmicroscope,
and the mean cellular adhesion rate was calculated.
Attachment to Extracellular Matrix Components
Six-well plates (Falcon Primaria) were coated with collagen G
[extracted from calfskin, consisting of 90% collagen type I and 10%
collagen type III; diluted to 400 μg/ml in phosphate-buffered saline
(PBS); Seromed, Berlin, Germany] or fibronectin (derived from human
plasma, diluted to 50 μg/ml in PBS; BD Biosciences) overnight.
Unspecific cell binding was evaluated using culture plates treated with
Poly-D-Lysine (Nunc, Wiesbaden, Germany). Plastic dishes served as
the background control. Plates were washed with 1% BSA in PBS to
block nonspecific cell adhesion. Tumor cells (0.5 x 106) were then added
to each well for 30minutes. Subsequently, nonadherent tumor cells were
washed off, and the remaining adherent cells were fixed with 2%
glutaraldehyde and counted under a microscope. The mean cellular
adhesion rate, defined by adherent cellscoated well − adherent cellsbackground,
was calculated from five different observation fields (5 × 0.25 mm2).
Tumor Cell Motility (Chemotaxis)
Serum-induced chemotactic movement was investigated using six-
well Transwell chambers (Greiner Bio-One, Frickenhausen, Germany)
with 8-μm pores. RCC cells (0.5 × 106) per milliliter were placed
in the upper chamber in serum-free medium. The lower chamber
contained 10% serum. After 20-hour incubation, the upper surface of
the Transwell membrane was gently wiped with a cotton swab to
remove nonmigrating cells. Cells, which hadmoved to the lower surface
of the membrane, were stained using hematoxylin and counted under
a microscope. The mean chemotaxis rate was calculated from five
different observation fields (5 × 0.25 mm2).
Integrin Surface Expression
RCC cells were detached from their culture flasks by Accutase
(PAA Laboratories GmbH, Pasching, Austria) and washed in
blocking solution (PBS, 0.5% BSA). The cells were then incubated
for 60 minutes at 4°C with phycoerythrin (PE)-conjugated
monoclonal antibodies (mAbs) directed against the following integrin
subtypes: anti-a1 (mouse IgG1, clone SR84), anti-a2 (mouse IgG2a,
clone 12 F1-H6), anti-a3 (mouse IgG1, clone C3 II.1), anti-a4
(mouse IgG1, clone 9 F10), anti-a5 (mouse IgG1, clone IIA1), anti-
a6 (rat IgG2a, clone GoH3), anti-b1 (mouse IgG1, clone MAR4),
anti-b3 (mouse IgG1, clone VI-PL2), or anti-b4 (rat IgG2a; clone
439–9B; all: BD Biosciences). Tumor cell integrin expression was
then measured using a FACScan (BD Biosciences; FL-2H (log)
Neoplasia Vol. 16, No. 4, 2014 Temsirolimus Resistance of Renal Carcinoma Cells Juengel et al. 293channel histogram analysis; 1 × 104 cells per scan) and expressed as
mean fluorescence units. A mouse IgG1-PE (MOPC-21) or IgG2a-
PE (G155–178; all: BD Biosciences) was used as an isotype control.
Western Blot Analysis
To investigate the integrin protein level in Cakires and Cakipar
cells, tumor cell lysates were applied to a 7% to 12% polyacrylamide
gel and electrophoresed for 90 minutes at 100 V. The protein was
then transferred to nitrocellulose membranes (1 hour, 100 V). After
blocking with nonfat dry milk for 1 hour, the membranes were
incubated overnight with mAbs directed against integrin α3 (rabbit,
polyclonal, 1:1000; Chemicon/Millipore, Schwalbach, Germany),
integrin α5 (mouse IgG2a, 1:5000, clone 1; BD Biosciences), and
integrin β3 (mouse IgG1, 1:2500, clone 1; BD Biosciences).
HRP-conjugated goat anti-mouse IgG and HRP-conjugated goat
anti-rabbit IgG (both: 1:5.000; Upstate Biotechnology, Lake Placid,
NY) served as the secondary antibody. The membranes were briefly
incubated with ECL detection reagent (ECL; Amersham/GE Health-
care,München,Germany) to visualize the proteins and then analyzed by
the Fusion FX7 system (Peqlab, Erlangen, Germany). β-Actin (1:1.000;
clone AC-15; Sigma-Aldrich, Taufenkirchen, Germany) served as the
internal control.0
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Figure 1. Adhesion and chemotactic behavior of temsirolimus-resis
adhesion to HUVEC after 60 minutes. (B) Adhesion to the extracellular
(par) RCC cells were added to immobilized collagen or fibronectin for 6
was assessed in a Transwell chamber assay. Tumor cells were seeded
chemoattractant, was placed in the lower well. A to C show means
experiments. * indicates significant difference between the resistantBlocking and Knockdown Studies
RCC cells were incubated for 60 minutes with 10 μg/ml function-
blocking anti–integrin β3 (clone B3A) or anti–integrin α5 (clone
P1D6) mouse mAb (both: Millipore). Control cells were incubated
with cell culture medium alone.
Additionally, tumor cells (3 × 105 per well) were transfected with
small interfering RNA (siRNA) directed against integrin β3 (2 μM,
HS_ITGB3_5 FlexiTube siRNA: NM_000212; Qiagen, Hilden,
Germany) or integrin α5 (2 μM, Hs_ITGA5_5 FlexiTube siRNA:
NM_002205; Qiagen) with a siRNA/transfection reagent (HiPerFect
Transfection Reagent; Qiagen) ratio of 1:6. Nontreated cells and cells
treated with 5 nM control siRNA (AllStars Negative Control siRNA;
Qiagen) served as controls. Subsequently, tumor cell adhesion to
HUVEC, immobilized collagen, or fibronectin as well as RCC
chemotaxis were analyzed as indicated above.
Statistics
All experiments were performed three to six times. Statistical
significance was calculated with the Wilcoxon–Mann-Whitney U
test. Differences were considered statistically significant at a P value
less than .05. Inhibitory concentration of 50% (IC50) values were
calculated by CalcuSyn software (Biosoft, Cambridge, UK).0
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matrix proteins collagen and fibronectin. Resistant (res) or sensitive
0 minutes, and binding wasmeasured. (C) Chemotactic movement
in the upper chamber in serum-free medium, and 10% FCS, as the
calculated from five counts. Each diagram represents one of six
and the sensitive tumor cell subline.
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Tumor Cell Adhesion and Chemotaxis
IC50 values were given as follows: A498
par = 3.32 ± 0.82; A498res =
17.01 ± 0.32; KTCpar = 0.49 ± 0.18; KTCres = 29.73 ± 8,76; Cakipar =
7.41 ± 3.24; and Cakires = 160.53 ± 46.71 (each: nM/ml). Evaluation
of tumor cell endothelial cell interaction revealed that more A498res,
KTCres, or Cakires cells adhered to HUVEC than did the
respective parental cell lines (Figure 1A). Similar behavior was
apparent for the matrix binding assay. Significantly more A498res,
KTCres, or Cakires cells bound to immobilized fibronectin (but not
to collagen) compared to A498par, KTCpar, or Cakipar (Figure 1B).
Regarding chemotaxis, more A498res, KTCres, or Cakires cells
penetrated the Transwell membrane, compared to the parental cell
lines (Figure 1C).
Tumor cells were retreated with a therapeutically relevant
temsirolimus concentration (10 nM), and the response was analyzed.
Drug treatment caused a significant reduction in the number of drug-
sensitive cells adhering to HUVEC. This effect was not found in the
resistant cell lines (Figure 2A, representative for KTCTL-26).
Adhesion of A498par, KTCpar, or Cakipar to collagen or fibronectin0
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Figure 2. Short-term treatment with low-dosed temsirolimus differe
RCC cells. The resistant tumor cells were treated with fresh mediu
temsirolimus. Medium change followed by 10 nM temsirolimus treatm
time-dependent RCC adhesion to HUVEC (representative for KTCpar an
C demonstrates chemotactic behavior of the tumor cell sublines
Percentage is related to controls not treated with 10 nM temsirolimu
* indicates significant difference to the temsirolimus-free control.
sensitive RCC cell line.increased with 10 nM temsirolimus. However, temsirolimus did not
elevate A498res, KTCres, or Cakires cell binding to collagen, and the
number of bound cells was even diminished in the fibronectin-coated
plates, compared to nontreated cells (Figure 2B). Inversely,
chemotactic movement of A498par, KTCpar, or Cakipar was
diminished, whereas this was not true with respect to A498res,
KTCres, or Cakires cells. Chemotaxis of the resistant cell lines was
increased, compared to the controls (Figure 2C).
Because all cell lines responded similarly to temsirolimus,
subsequent experiments were limited to the cell line KTCTL-26.
Integrins Are Modified in KTCres Cells
Surface levels of integrin α and β adhesion receptors were analyzed
by a FACScan. The integrin subtypes α3 and β1 were strongly
expressed, and α1, α2, α5, and β3 were moderately expressed,
whereas α6 and β4 were only minimally detectable on KTCpar cells
(Figure 3A). Comparative analysis between KTCpar and KTCres cells
revealed distinct differences of the integrin expression pattern. The
α3 integrin subtype was slightly elevated, and the β3 subtype member
was strongly enhanced, whereas integrin α5 was dramatically
downregulated on the KTCres cell membrane, compared to KTCpar0
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Figure 3. Integrin α and β expression in KTCpar and KTCres cells. A depicts the FACS results given as mean fluorescence units. Tumor cells
were washed in blocking solution and then stained with specific mAbs as listed in Materials and Methods section. To evaluate
background staining of PE-conjugated antibodies, goat anti-mouse IgG1-PE or IgG2a-PE was used. Fluorescence was measured using a
FACScan flow cytometer. * indicates significant difference between the resistant and the sensitive tumor subline. (B) Modification of
intracellular integrin protein level. Tumor cell lysates were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
blotted on the membrane incubated with appropriate mAbs. β-Actin served as the internal control. The figure shows one representative
from three separate experiments.
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α2, α6, β1, and β4 integrins.
According to the flow cytometry data, integrin α3 protein was
elevated, and α5 protein diminished in KTCres compared to KTCpar
cells. The β3 integrin protein content was lowered in the drug-
resistant tumor cells, compared to the drug-sensitive cells (Figure 3B).
This finding contrasts with the FACS data demonstrating β3 up-
regulation under resistance.
Blocking Studies
Blocking studies were carried out to investigate the functionality of
α5 and β3 integrins, which were most strongly altered in KTCres
compared to KTCpar cells. Blockade of α5 on the cell surface by a
mAb led to significant enhancement of tumor cell adhesion to
HUVEC (Figure 4A). The effect was more pronounced in KTCres
compared to KTCpar cells. Integrin α5 blockade correlated with an
increased binding of KTCpar but with a decreased binding of KTCres
cells to collagen. Inversely, α5 blocking reduced KTCpar binding but
elevated KTCres binding to fibronectin (Figure 4B). The motile
behavior of KTCpar and KTCres cells was influenced by α5, in as
much as receptor blockade triggered a distinct (KTCpar) or moderate
(KTCres) loss of chemotactic activity (Figure 4C).
Knocking down the intracellular integrin α5 content by siRNA
(Western blot controls are shown in Figure 5A) diminished the
interaction of both KTCpar and KTCres cells with endothelium as
well as with the matrix proteins collagen and fibronectin, compared tountreated controls (Figure 5B). Chemotaxis was not influenced
(Figure 5C) with no differences between KTCpar and KTCres cells.
Experiments were repeated using a β3 integrin–blocking antibody.
In doing so, tumor cell adhesion to HUVEC was significantly
lowered, compared to the untreated controls (Figure 6A), whereby no
quantitative differences were seen between KTCpar compared to
KTCres cells. A similar phenomenon was induced in the collagen and
fibronectin binding assay (Figure 6B). Integrin β3 blockade also
prevented integrin migration through the transmembrane pores.
However, the number of migrating KTCres cells was reduced to a
higher extent than for KTCpar cells (Figure 6C).
Chemotaxis of the KTCTL-26 tumor cells whose β3 integrin had
been knocked down was additionally investigated. This led to a
significant reduction of KTCpar migration, whereas motility of
KTCres cells was upregulated (Figure 7).
Discussion
Evidence is presented here showing that temsirolimus resistance is
coupled to enhanced RCC cell adhesion to vascular endothelium and
to extracellular matrix components, accompanied by increased
chemotactic activity. Transendothelial migration and motile spread-
ing are critical steps in tumor dissemination and progression [11].
With this in mind, it is concluded that long-term exposure to
temsirolimus may alter the invasive behavior, creating highly
aggressive RCC cells. Interaction of the drug-resistant tumor cells
with fibronectin, but not with collagen, was distinctly escalated. This
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Figure 4. Influence of integrin α5 blockade on tumor cell adhesion to HUVEC (A), binding to immobilized collagen or fibronectin (B) and on
chemotaxis (C). KTCpar or KTCres cells were preincubated for 60 minutes with a function-blocking anti–integrin α5 mAb. Controls were
untreated. Values are percentage difference to the 100% control. * indicates significant difference between the RCC control subline and
the RCC subline treated with the function-blocking antibody. # indicates significant difference between KTCpar and KTCres cells whose
integrin subtype was blocked.
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that fibronectin is the dominant factor promoting lung metastasis of
RCC [9]. In good accordance, comparative analysis of primary and
metastatic RCC cells displayed an increased capacity of the metastatic
subtype to strongly attach to fibronectin, whereas cross talk with
collagen was only of minor relevance [12]. Therefore, long-term use
of temsirolimus may change the RCC phenotype, driving the
fibronectin-dependent invasion process forward. This hypothesis is
supported by the present investigation, whereby the tumor cells
exposed to a therapeutically relevant temsirolimus dosage exhibit
altered binding of the resistant RCC cells only to fibronectin. In
contrast, both collagen and fibronectin binding to temsirolimus-
sensitive RCC cells was altered, with collagen-dependent adhesion
being more modified than fibronectin-dependent adhesion.
In drug-resistant prostate cancer cells, an inverse correlation
between adhesion and migration properties has been reported [10].
Although the complex scenario of metastatic colonization is not fully
understood, there is no doubt that loosening tumor-matrix contact is
a necessary prerequisite to allow motile crawling into the surrounding
tissue [11,13]. It is therefore not surprising that the basal attachment
rate of the drug-resistant RCC to fibronectin was higher than the one
of the drug-sensitive cells but was then diminished under short-term
retreatment with low-dosed temsirolimus. At the same time, theresistant tumor increased its motile activity, indicating a behavioral
switch from being adhesive to becoming invasive. Such a two-step
process could play a role during resistance acquisition. The first step
may involve facilitating fibronectin instead of collagen-dependent
tumor-matrix interaction, and the second step may involve a
conversion from an adhesive to an invasive phenotype. Isogai et al.
have defined a critical role of fibronectin in providing a cellular switch
between stationary and migratory cell phases [14], which would
support this hypothesis.
The mechanism responsible for increased motile behavior indicates
modification of the integrin expression pattern. The α5 integrin
subtype was drastically downregulated on the surface membrane as
well as within the cytoplasm of drug-resistant RCC cells. Detailed
information on the role of integrin α5 is sparse. Studies on A498 cells
have revealed that α5 regulates tumor binding to fibronectin [15] and
controls chemotaxis [16]. This corroborates the present data
demonstrating diminished contact of KTCpar cells to fibronectin
and reduced migratory potential once α5 surface expression has been
blocked. Nevertheless, the situation appears more complex than
initially thought because KTCres behaved differently under α5
blockade, compared to the KTCpar cells. The pronounced effect of
α5 on KTCpar chemotaxis was not seen with KTCres. Most notably,
attachment of KTCres to collagen was inhibited, and attachment to
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Figure 5. Influence of integrin α5 knockdown on tumor cell adhesion andmotility. KTCpar and KTCres cells were transfected with α5 siRNA
or scrambled siRNA, and knockdown was controlled by Western blot analysis (A). Cells were then subjected to the HUVEC, collagen, and
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diagram represents one of six experiments. * indicates significant difference to the siRNA-free control.
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in the opposite way. Obviously, the relevance of the α5 receptor for
KTCpar is not transferable to the KTCres cells. On the basis of the
present investigation, a functional switch of the α5 integrin during
resistance development is proposed, in as much as this integrin
subtype may no longer control the tumor cell's motility but rather
shifts the tumor cell's binding affinity from collagen to fibronectin.
Change of the integrin function seems also to be reflected in the
endothelial cell binding assay, because blocking α5 distinctly
enhanced KTCres but only slightly elevated KTCpar adhesion to
HUVEC. Apart from hypothesizing differences in linking α5 to a
(still unknown) endothelial cell receptor, HUVECs are predestined to
deposit collagen and fibronectin on their surface [17]. Given that
matrix proteins serve as the specific integrin ligands [18], α5 may
promote KTCres accumulation along the endothelial fibronectin
fibers. However, involvement of α5 in KTCpar adhesion includes
both collagen and fibronectin with a reciprocal relationship.
Consequently, only mild alterations of KTCpar binding to
HUVEC in the presence of the α5 antibody can be expected.
The different effects of α5 on temsirolimus-responsive compared
to temsirolimus-nonresponsive RCC cells were not inducible by
knocking down the α5 protein content. Therefore, it seems likely that
the α5 surface receptor is the relevant factor responsible for modifyingtumor cell adhesion. Loss of α5 together with a functional switch has
recently been observed in everolimus-resistant prostate cancer [10].
Presumably, the role of α5 seen in drug-resistant RCC is not
restricted to this tumor entity. Nevertheless, further experiments on
different tumor types are required to investigate whether the role of
the α5 integrin in mTOR inhibitor–based regimen can be
generalized.
Blocking the β3 integrin surface molecule diminished RCC
chemotaxis with KTCres being more influenced than KTCpar cells.
Considering the strong elevation of this receptor on the KTCres
membrane, it seems likely that membranous β3 is, at least partially,
responsible for the enhanced migratory activity seen in the resistant
RCC tumor cells. Because the β3 level inversely correlates with the
KTCres-binding activity, receptor enhancement might also be
responsible for fibronectin detachment occurring during temsiroli-
mus retreatment. Although no data from others are available
regarding this issue, β3 integrin expression correlated well with the
invasive potential of lung [19], breast [20], and colorectal [21]
carcinomas as well as of melanoma cells [22]. Classification of 45
human tumor cell lines derived from various tissues has revealed cell
surface localization of β3 integrin receptors exclusively in cell lines
crossing an endothelial cell barrier [23]. Hence, upregulating β3 along
the RCC cell surface under chronic temsirolimus treatment might
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Figure 6. Integrin β3 blocking studies. KTCpar or KTCres cells were preincubated for 60 minutes with a function-blocking anti–integrin β3
mAb, and tumor cell adhesion to HUVEC (A), tumor cell binding to immobilized collagen or fibronectin (B), and chemotactic motility (C)
were evaluated. Controls remained untreated. Each experiment was repeated five times. Mean values from one representative test
are shown as percentage difference to the 100% control. * indicates significant difference between the control RCC and RCC cells
treated with the function-blocking antibody. # indicates significant difference between KTCpar and KTCres cells whose integrin subtype
was blocked.
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development of undesired countermechanisms caused by an mTOR
inhibitor regimen should therefore be carefully controlled. Whether0
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down differentially altered the chemotactic activity of KTCpar,
compared to KTCres cells. Indeed, loss of this protein significantly
lowered KTCpar but increased KTCres chemotaxis. Reduction of
the intracellular β3 content, becoming overt during resistance
acquisition, is therefore a signal that RCC cells undergo conversion
toward a highly motile phenotype. Because loss of cytoplasmic β3
is paralleled by enrichment of this receptor on the cell membrane,
it may be assumed that β3 is translocated from the intracellular
space to the outer cell surface. The same reciprocal distribution of
β3 has been observed in Caki res and A498res, indicating a common
mechanism of redistribution (data not shown). Indeed, trafficking
integrins has been documented to play an important role in
regulating invasive migration [24]. Because both reduced intracel-
lular β3 as well as enhanced β3 surface expressions separately
promote RCC migration, dynamic receptor trafficking may further
encourage metastatic dissemination.
The different chemotactic response of sensitive and resistant tumor
cells in the presence of β3 siRNA points to a functional switch of the
β3 integrin, as has already been postulated with the α5 molecule. The
α5 subtype forces fibronectin-RCC interaction, possibly as a
prerequisite for initiating invasion, whereas β3 drives the invasion
process forward. The molecular background underlying the func-
tional switch of α5 and β3 is still a matter of debate. Flevaris et al.
indicate that the β3 integrin may inhibit the RhoA signaling pathway,
subsequently inducing the conversion from adhesion to migration
[25]. This is important because everolimus has recently been
demonstrated to prevent migration of drug-sensitive cells by RhoA
activation [26] and, consequently, activates the motile machinery by
diminishing RhoA. Although how RhoA contributes to the
conflicting processes of stable adhesion and motile spreading is not
well understood, it is plausible to assume modification of the β3-
RhoA cross-communication in RCC cells during resistance develop-
ment. Whether this speculation is transferable to the α5 integrin is
not yet clear. However, a link from α5 to RhoA has recently been
observed in melanoma cells [27], making the existence of an α5-
RhoA axis in RCC cells likely.
This study shows that temsirolimus resistance drives RCC cancer
cells to become highly motile. The process is accompanied by two
different processes: 1) quantitative alteration of the integrin α5 and
β3 expression and 2) functional change of the integrin molecules,
forcing the switch from adhesion to migration. Analysis of the
integrin-driven alterations of the intracellular signaling machine is the
subject of ongoing experiments.
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